Matching articles for "Natrecor"
In Brief: Nesiritide (Natrecor)
The Medical Letter on Drugs and Therapeutics • November 14, 2011; (Issue 1377)
A recent editorial in The New England Journal of Medicine commented on the negative results of a clinical trial (published in the same issue) of nesiritide, a drug that had been approved by the FDA in 2001...
A recent editorial in The New England Journal of Medicine commented on the negative results of a clinical trial (published in the same issue) of nesiritide, a drug that had been approved by the FDA in 2001 (conditionally approved by Health Canada in 2007) for relief of dyspnea in patients with acutely decompensated heart failure. The authors of the recent clinical trial concluded: "On the basis of these results, nesiritide cannot be recommended for routine use in the broad population of patients with acute heart failure."1 The editorialist lamented the inadequacy of the data that had led to the approval of the drug in the first place, the 10 years of "fuzziness and ambiguity" that had followed regarding its use, and the "more than $1 billion" wasted on buying it.2
In 2001, when nesiritide was first approved in the US, The Medical Letter also expressed dissatisfaction with the quality of the data criticized by the 2011 editorialist, and concluded its assessment of nesiritide as follows: "Until more published data become available, nesiritide should probably be reserved for treatment of patients with heart failure who have not responded to nitroglycerin and cannot be treated with nitroprusside."3
1. CM O’Connor et al. Effect of nesiritide in patients with acute decompensated heart failure. N Engl J Med 2011; 365: 32.
2. EJ Topol. The lost decade of nesiritide. N Engl J Med 2011; 365:81.
3. Nesiritide for decompensated congestive heart failure. Med Lett Drugs Ther 2001; 43:100.
Download U.S. English
In 2001, when nesiritide was first approved in the US, The Medical Letter also expressed dissatisfaction with the quality of the data criticized by the 2011 editorialist, and concluded its assessment of nesiritide as follows: "Until more published data become available, nesiritide should probably be reserved for treatment of patients with heart failure who have not responded to nitroglycerin and cannot be treated with nitroprusside."3
1. CM O’Connor et al. Effect of nesiritide in patients with acute decompensated heart failure. N Engl J Med 2011; 365: 32.
2. EJ Topol. The lost decade of nesiritide. N Engl J Med 2011; 365:81.
3. Nesiritide for decompensated congestive heart failure. Med Lett Drugs Ther 2001; 43:100.
Download U.S. English
Cardiovascular Drugs in the ICU
The Medical Letter on Drugs and Therapeutics • December 1, 2002; (Issue 4)
Ever-increasing specialization has made it difficult for many physicians to keep up with therapeutic standards in intensive-care units (ICUs). This issue of Treatment Guidelines offers current recommendations...
Ever-increasing specialization has made it difficult for many physicians to keep up with therapeutic standards in intensive-care units (ICUs). This issue of Treatment Guidelines offers current recommendations for use of cardiovascular drugs in the ICU for treatment of hypertensive emergencies; shock, cardiac arrest or decompensated heart failure; and ventricular arrhythmias.
Nesiritide For Decompensated Congestive Heart Failure
The Medical Letter on Drugs and Therapeutics • November 12, 2001; (Issue 1118)
Nesiritide, a recombinant human B-type natriuretic peptide (BNP), has been approved by the FDA of intravenous (IV) treatment of patients with decompensated congestive heart failure who have dyspnea at rest or...
Nesiritide, a recombinant human B-type natriuretic peptide (BNP), has been approved by the FDA of intravenous (IV) treatment of patients with decompensated congestive heart failure who have dyspnea at rest or with minimal exertion (New York Heart Association class IV).